B.C. biotech company says, despite interim approval, provinces won’t use its COVID-19 treatment – CBC.ca

Article feature image

The CEO of a B.C. biotechnology company says the treatment his firm has developed for COVID-19 is sitting on shelves while people continue to die, despite it being approved for use by Health Canada in the fall. 
“Canada was quick to authorize it. The federal government moved quickly to procure it. So we signed a procurement agreement and bought doses back in November,” Dr. Carl Hansen, co-founder and CEO of Vancouver-based AbCellera, told CBC News Network’s Power & Politics. 
“But because of some…

Click here to view the original article.

S&P/ASX 200 
7,065.60  2.10  0.03%  
ALL ORDINARIES 
7,328.00  2.20  0.03%  
Dow Jones Industrial Average 
34,200.67  164.67  0.48%  
S&P 500 
4,185.47  15.05  0.36%  
NASDAQ Composite 
14,052.34  13.54  0.10%  
NYSE COMPOSITE (DJ) 
16,186.30  69.50  0.43%  
FTSE 100 
7,036.40  16.87  0.24%  
DAX PERFORMANCE-INDEX 
15,450.72  9.03  0.06%  
Nikkei 225 
29,685.37  2.00  0.01%  
HANG SENG INDEX 
29,106.15  136.44  0.47%